Holly Groteluschen, MD
Family Medicine · Kearney, NENPI 1104449149
Payments from drug & device makers
Across 50 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$250
- AbbVie$245
- Novo Nordisk$134
- Organon$95
- Otsuka America Pharmaceutical, Inc.$91
- Pulmonx Corporation$43
- plus $261 from 11 others
What the payments were for
- Food & beverage$1,120100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 1 | $250 |
| AbbVie | 18 | $245 |
| Novo Nordisk | 9 | $134 |
| Organon | 3 | $95 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Pulmonx Corporation | 1 | $43 |
| Lundbeck LLC | 2 | $35 |
| Exact Sciences | 2 | $35 |
| Merck | 1 | $31 |
| GSK | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Pfizer | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Biogen | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOWST$250
How this compares
$1,120 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 21 | $734 |
| Pantoprazole Sodium | 25 | $488 |
| Atorvastatin Calcium | 28 | $354 |
| Omeprazole | 14 | $281 |
| Gabapentin | 40 | $235 |
| Amlodipine Besylate | 28 | $187 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $183 |
| Levothyroxine Sodium | 25 | $173 |
| Simvastatin | 27 | $166 |
| Metformin Hcl | 18 | $109 |
| Memantine Hcl | 12 | $107 |
| Hydrochlorothiazide | 26 | $99 |
| Losartan Potassium | 13 | $98 |
| Alendronate Sodium | 11 | $94 |
| Lisinopril | 18 | $74 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Kearney
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.